Indications for single-dose activated charcoal administration in acute overdose

Area of Science:

• Emergency Medicine
• Clinical Toxicology
• Pharmacology

Background:

• Gastrointestinal decontamination in overdose cases is debated.
• Use of single-dose activated charcoal (SDAC) has declined despite limited new evidence.
• Low overall mortality in overdose patients may contribute to reduced SDAC use.

Purpose of the Study:

• To review the current evidence and clinical utility of single-dose activated charcoal (SDAC) in overdose patients.
• To evaluate the effectiveness of SDAC in reducing drug absorption and improving clinical outcomes.
• To inform clinical decision-making regarding SDAC administration in emergency medicine.

Main Methods:

• Review of human volunteer studies on SDAC efficacy.
• Analysis of randomized controlled trials (RCTs) investigating SDAC in overdose.
• Examination of pharmacokinetic and pharmacodynamic data for specific drugs.

Main Results:

• Human studies indicate SDAC is effective up to 4 hours post-ingestion, with diminishing benefits over time.
• Two RCTs, including a recent large study, found no significant benefit from SDAC.
• While SDAC reduces drug exposure for most substances, this does not always correlate with clinical benefit.

Conclusions:

• SDAC is unlikely to be beneficial for many overdose patients.
• For specific subgroups with severe poisoning, SDAC benefits may outweigh its low administration risk.
• SDAC use should be individualized, considering drug toxicity, potential benefits, and patient acceptance.